16 May 2012
Bristol-Myers Squibb will fund research efforts at Tsinghua University's School of Life Sciences to identify and validate novel targets in oncology and immunoscience.
14 Feb 2012
Bristol-Myers Squibb has announced the successful completion of the tender offer by Bristol-Myers Squibb Company for all of the outstanding shares of common stock of Inhibitex, Inc.
29 Jan 2012
Bristol-Myers Squibb posted fourth quarter 2011 net sales of $5.5 billion, an increase of 7% compared to the same period a year ago.
09 Jan 2012
BMS enjoyed a successful year, with several pipeline drugs reporting positive trial results and clearing regulatory hurdles.
09 Jan 2012
Bristol-Myers Squibb will acquire Inhibitex with an aggregate purchase price of approximately $2.5 billion.
23 Dec 2011
By identifying targets that prevent or reverse Tau dysfunction, BMS and Gladstone hope to identify novel therapeutic strategies to modify the course of the disease.
14 Dec 2011
Simcere will receive exclusive rights to develop and commercialize BMS-795311 in China while Bristol-Myers Squibb will retain exclusive rights in all other markets.
05 Dec 2011
The companies will evaluate the potential to achieve sustained viral response 12 and 24 weeks post treatment in patients with HCV genotype 1 in a study with three treatment regimens.
27 Oct 2011
The companies have signed a licensing agreement for the development and commercialization of the REYATAZ and cobicistat fixed-dose combination.
23 Sep 2011
New York-based Bristol-Myers Squibb has inked an agreement with Ambrx to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein and the Relaxin hormone.
Items per Page 10 | Total 3 Pages | Go to Page [2] [3] Next»»
